SELLAS arbitration claims against 3D Medicines dismissed; unaudited cash $138.3 million
An arbitrator dismissed SELLAS's claims against licensee 3D Medicines on July 24, 2026, and allocated about $1.0 million of 3D Medicines' legal fees and costs to be paid by SELLAS. The filing also gives unaudited cash and cash equivalents of $138.3 million as of June 30, 2026, which may differ materially from the figures in the company's final financial statements. The dismissal removes SELLAS's claims over $13.0 million in disputed milestone payments, while 3D Medicines says it will continue developing galinpepimut-S in Greater China.
Key points
- On July 24, 2026, the sole arbitrator in the HKIAC arbitration dismissed SELLAS's claims against 3D Medicines.
- SELLAS must pay approximately $1.0 million of 3D Medicines' legal fees and costs, as allocated by the arbitrator.
- Unaudited cash and cash equivalents were $138.3 million as of June 30, 2026, subject to financial closing procedures.
- $191.5 million in potential future milestone payments remained under the license as of March 31, 2026, including the $13.0 million in dispute.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.